|
|
|
Hair Loss Study Abstract: Effects of a new steroidal antiandrogen, TZP-4238 (17 alpha-acetoxy-6-chloro-2-oxa-4, 6-pregnadiene-3, 20-dione), on spontaneously developed canine benign prostatic hyperplasia.
|
Title
Effects of a new steroidal antiandrogen, TZP-4238 (17 alpha-acetoxy-6-chloro-2-oxa-4,
6-pregnadiene-3, 20-dione), on spontaneously developed canine benign prostatic
hyperplasia.
Author
Takezawa Y; Ito K; Suzuki K; Fukabori Y; Yamanaka H; Honma S; Mieda M; Hamataki N;
Kushitani M
Address
Department of Urology, Gunma University School of Medicine, Maebashi, Japan.
Source
Prostate, 27: 6, 1995 Dec, 321-8
Abstract
The effects of the new steroidal antiandrogen, TZP-4238 on spontaneously-developed
canine prostatic hyperplasia (BPH) were studied in comparison with those of chlormadiNone
acetate (CMA), a steroidal antiandrogen used for the treatment of BPH and prostatic cancer
in Japan. Aged beagle dogs (5-9 years old) with spontaneously developed BPH (mean prostate
volume, 17.7ml) were treated orally with a placebo, TZP-4238 (0.1 mg/kg/day, 0.01
mg/kg/day), or CMA (3 mg/kg/day), for 25 weeks. Prostate volume was measured by
transrectal ultrasonography before treatment and every 5 weeks during treatment. TZP-4238
produced a regression in spontaneously developed canine BPH, its effects being more potent
than those of CMA. TZP-4238 reduced the content of testosterone, dihydrotestosterone (DHT)
and androgen receptor in the prostates of these animals, suggesting antiandrogenic
mechanisms of the agent. TZP-4238 also appeared to reduce 5 alpha-reductase activity by
prevention of the androgen action in prostate as described above.
Language of Publication
English
Unique Identifier
96105449
content2 |
|
